Elevance Health, IncNYSE: ELV
Health Care · Managed Health Care
$397.94
-0.98%
Vol: 178K
Research Digest
Tuesday, June 16, 2026
No significant overnight updates
No material news in the last 48 hours. Elevance reaffirmed its 2026 EPS guidance on June 10 and received price-target raises June 8-9, but these fall outside the window; only a minor director insider sale was logged June 11.
Previous Market Intelligence
13 daysJun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 20Elevance shareholders re-elect directors and back pay at May 13 annual meeting after BofA upgrade lifts sentiment.Positive▶
On May 13, 2026, Elevance Health shareholders re-elected three directors—Gail Boudreaux, Robert Dixon Jr., and Deanna Strable—to three-year terms ending 2029 and approved executive compensation and Ernst & Young as auditor; a shareholder proposal on political contributions failed. BofA analyst Kevin Fischbeck upgraded ELV to Buy from Neutral with a $435 price target (up from $405), citing improving Medicaid margins. The company recently reported a Q1 beat with adjusted EPS of $12.58 vs. $10.80 consensus, raised full-year adjusted EPS guidance to at least $25.50, and repurchased ~$1.1 billion of stock in the quarter. The stock has rallied 23.8% over the past month on the back of stronger earnings and guidance. Eighteen analysts maintain a Buy consensus.
May 19No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 18Elevance Health held its 2026 Annual Meeting on May 13 with three directors reelected to three-year terms, following a Q1 earnings beat with adjusted EPS of $12.58 vs. $10.80 consensus and raised FY26 guidance.Positive▶
On May 13, 2026, Elevance Health held its Annual Meeting of Shareholders where three directors—Gail K. Boudreaux, Robert L. Dixon Jr., and Deanna D. Strable—were elected to new three-year terms ending in 2029, with more than 194 million shares represented. Shareholders approved executive compensation on an advisory basis and ratified Ernst & Young as auditor for FY2026. In early May, Elevance reported Q1 2026 adjusted EPS of $12.58 vs. the $10.80 consensus (FactSet had $11.03), helped by $1 of nonrecurring investment income, with 2% revenue growth, and raised full-year 2026 adjusted EPS guidance to at least $25.50. The company repurchased about $1.1 billion of stock in Q1. BofA analyst Kevin Fischbeck upgraded ELV to Buy from Neutral with a $435 price target (up from $405). ELV declared a $1.72 cash dividend with an ex-date of June 10, 2026. Consensus rating from 18 analysts is Buy as of May 5, 2026.
May 15Elevance Health shareholders re-elected three directors at May 13 annual meeting after company raised FY26 EPS guidance to at least $26.75.Positive▶
Elevance Health's May 13 annual meeting elected Gail Boudreaux, Robert Dixon Jr., and Deanna Strable to three-year terms ending in 2029, with shareholders also approving executive compensation and ratifying Ernst & Young as auditor. After a strong Q1 (adjusted EPS $12.58 vs $10.80 consensus), Elevance has now raised FY26 adjusted EPS guidance to at least $26.75, up from at least $25.50. The company repurchased ~$1.1B of stock in Q1. BofA's Kevin Fischbeck upgraded ELV to Buy from Neutral with a $435 PT (from $405). Concerns about elevated medical cost pressures and CMS regulatory uncertainty remain.
May 14Elevance Health shareholders re-elected directors and ratified pay at the May 13 annual meeting, capping a strong Q1 with raised 2026 guidancePositive▶
At its May 13, 2026 annual meeting, Elevance Health shareholders elected directors Gail K. Boudreaux, Robert L. Dixon Jr., and Deanna D. Strable to new three-year terms through 2029, approved executive compensation on an advisory basis, and ratified Ernst & Young as auditor for FY26. The vote follows a Q1 2026 beat in which adjusted EPS reached $12.58 versus the $10.80 consensus, with full-year adjusted EPS guidance raised to at least $25.50, driven by improved medical cost management. Elevance repurchased roughly $1.1 billion of stock in Q1 even while facing regulatory uncertainty. On May 1, the company recognized best-in-class primary care practices under its care provider program. The governance vote and EPS guidance lift validate the post-pandemic medical cost normalization thesis. The bear case: industry-wide medical cost trend remains uneven, and regulatory pressure on Medicare Advantage rates and PBM practices is an ongoing overhang.
May 13Elevance Health continues working with CMS on Medicare Advantage data review, with the sanctions deadline extended to May 30, while building on a Q1 earnings beat.Mixed▶
Elevance reported Q1 2026 adjusted EPS of $12.58 (vs $10.80 consensus) and raised full-year adjusted EPS guidance to at least $25.50, driven by strong medical cost management. The company repurchased ~$1.1B of stock in Q1. CMS has extended its Medicare Advantage data review until May 30, 2026, postponing potential sanctions originally set for March 31, creating ongoing regulatory overhang. Throughout May, the company is highlighting Mental Health Month initiatives backed by $23M in Foundation grants. BofA upgraded to Buy in late April; JPMorgan raised PT to $411 from $397.
May 12Elevance reshapes leadership as Carelon President Peter Haytaian exits May 4; CFO Mark Kaye takes oversight.Positive▶
Elevance Health announced a leadership restructuring: EVP and Carelon President Peter D. Haytaian left his role effective May 4, 2026 and will serve as Special Advisor through year-end. CFO Mark Kaye now adds oversight of Carelon while Felicia Norwood leads a consolidated Health Benefits organization. The company reaffirmed its 2026 EPS guidance after a strong Q1 beat that drove BofA to upgrade ELV to Buy from Neutral on April 29. Average analyst price target sits at $383.56 with a Buy consensus from 19 analysts. Elevance is also lighting offices green for Mental Health Month and committed $23 million in Foundation grants supporting community-based behavioral health.
May 11Elevance Health stock surged 23.8% over the past month following Q1 beat, raised full-year guidance, and management restructuring.Positive▶
Elevance Health (ELV) reported a strong Q1 2026, beating revenue and adjusted EPS expectations and raising full-year guidance, with shares surging 23.8% over the past 30 days through early May. Peter D. Haytaian transitioned from President of Carelon effective May 4, 2026 as part of management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. On May 4, the company announced expanded efforts to address mental health care challenges with $23 million in active Foundation grants supporting community-based behavioral health organizations, alongside a 12-month national pilot to expand diaper access and study maternal/child health effects. Analyst consensus is Buy across 18 analysts with an average price target of $383.56. A DCF analysis suggests ELV is undervalued by 64.2%. Risk: 1-year return remains -8.3% and the company received only an interim CMS response on Medicare Advantage matters.
May 8Elevance Health Q1 beats; raises FY guidance; returned $1.5B capital to shareholdersPositive▶
Elevance Health reported Q1 2026 operating revenue of $49.5B (up 1.5% YoY) exceeding expectations on improving claims and higher Health Benefits premiums. Company raised full-year adjusted EPS guidance supported by greater visibility. Returned $1.5B capital to shareholders in Q1 and declared Q2 dividend of $1.72/share payable June 25. Analyst consensus Buy rating with $383.56 12-month target (3.24% upside from $372.92). Stock trading at market cap of $81B. BofA upgraded to Buy from Neutral on April 29.
May 6Elevance Health raises full-year 2026 adjusted EPS guidance to at least $26.75 on Q1 beatPositive▶
Elevance Health reported Q1 2026 operating revenue of $49.5B (up 1.5% YoY) ahead of expectations, raising full-year adjusted EPS guidance to at least $26.75 from prior levels. Company achieved stronger-than-expected Q1 with favorable ACA seasonality and improving claims experience. Deployed AI across clinical and administrative workflows targeting 70% reduction in prior auth denials. Medicare Advantage repositioning on track for 2% operating margin in 2026. Returned $1.5B to shareholders in Q1; declared $1.72/share dividend for Q2. BofA upgraded to Buy from Neutral on Medicaid margin trough. Average analyst PT is $383.56 (+3.2%).
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| UNHUNITEDHEALTH | $408.67 | -0.58% | +5.1% | 19.7x | 0.65 | $373.3B |
| ELVELEVANCE | $397.94 | -0.98% | +2.0% | 13.7x | 0.68 | $87.3B |
| HUMHUMANA | $377.00 | -0.86% | +24.3% | 24.2x | 0.77 | $45.7B |
| CNCCENTENE | $61.22 | -3.44% | +8.9% | 14.2x | 1.09 | $31.3B |
| MOHMOLINA | $202.82 | +0.47% | +9.2% | 21.8x | 0.80 | $10.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.